U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07230353) titled 'A Phase 1b Open-label Study to Evaluate Safety in Participants With Rheumatoid Arthritis' on Oct. 01.
Brief Summary: The purpose of this study is to determine the safety and tolerability of XmAb13676 in patients with rheumatoid arthritis. Participants will be given XmAb13676 subcutaneously (SC) by injection under the skin.
Study Start Date: Oct. 21
Study Type: INTERVENTIONAL
Condition:
Rheumatoid Arthritis
Intervention:
BIOLOGICAL: XmAb13676
Biological
Recruitment Status: RECRUITING
Sponsor: Xencor, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....